Warren Foust was named President and Chief Executive Officer of Staar Surgical Co, effective August 4, 2026. As of November 6, 2026, Staar Surgical Co has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 6, 2026, naming 1 appointment (Form 8-K, August 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Staar Surgical Co? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Staar Surgical Co reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Staar Surgical Co files it.
Also on the record for Staar Surgical Co
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 9.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Madison Avenue International LP | 8.4% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5.2% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 13.1% of the class | 5%+ stakes | Source |
| April 20, 2026 | Stake report, Schedule 13G, by Madison Avenue International LP | 5.8% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13D/A, by Broadwood Partners, L.P. | 32.6% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13D/A, by Broadwood Partners, L.P. | 31.1% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13D/A, by Yunqi Capital Limited | 6.5% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13D/A, by Yunqi Capital Limited | 6.5% of the class | 5%+ stakes | Source |
| December 17, 2025 | Stake report, Schedule 13D/A, by Broadwood Partners, L.P. | 30.2% of the class | 5%+ stakes | Source |
| December 11, 2025 | Stake report, Schedule 13D/A, by Yunqi Capital Limited | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Staar Surgical Co now and the warning signs.
Free to see. No signup.
Keep reading
More on Staar Surgical Co and the records around it.
Staar Surgical Co elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Broadwood Partners, L.P. also filed stake reports on 2 other companies: Insight Molecular Diagnostics Inc. (Apr 2026), Lineage Cell Therapeutics, Inc. (Nov 2025)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), Theravance Biopharma, Inc. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Staar Surgical Co
Get an email when Staar Surgical Co files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Staar Surgical Co?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Staar Surgical Co: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Staar Surgical Co covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 28 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-06 | In | President and Chief Executive Officer | 2026-08-04 | 8-K, 2026-08-06 |
Who leads Staar Surgical Co, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Warren Foust, appointed, effective 2026-08-04 (filed 2026-08-06).
New leaders reset buying decisions — get the Full Report on Staar Surgical Co: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President and Chief Executive Officer at Staar Surgical Co, with the record behind each one.
Find candidates like President and Chief Executive Officer at Staar Surgical CoEvery change, in the filing's words
Appointed: Warren Foust, President and Chief Executive Officer, effective 2026-08-04
On August 4, 2026, STAAR Surgical Company (the "Company" or "STAAR") announced that the Company's Board of Directors (the "Board") appointed Warren Foust as President and Chief Executive Officer ("CEO") and new member of the Board, effective August 4, 2026 (the "Effective Date").
- Mr. Foust, age 50, joined STAAR in April 2023 as Chief Operating Officer ("COO") and has served as Interim Co-CEO, President & COO since February 2026, and as President and COO since March 2025.
- Prior to joining STAAR, Mr. Foust served as Worldwide President, Johnson & Johnson Vision, Surgical, since December 2019.
- Mr. Foust will continue to participate in all other elements of the Company's executive compensation and benefits plans.
- The Foust Agreement also provides for customary restrictive and confidentiality covenants.
- Vesting requires attainment of both the time and stock price targets referenced.
- Approximately one-third of the equity compensation is for 2026, and the remaining approximately two-thirds represent a pull forward of Mr. Foust's 2027 equity grant.
- Timing of Grants: The 2027 Time-Vesting Option and 2027 Performance-Vesting Option will be granted in two portions.
- The first portion, consisting of 37,962 of the 2027 Time-Vesting Option and 123,659 of the 2027 Performance-Vesting Option (the "First Portion of 2027 Options"), will be granted on the First Grant Date (as defined below).
- The second portion, consisting of 42,980 of the 2027 Time-Vesting Option and 140,005 of the 2027 Performance-Vesting Option (the "Second Portion of 2027 Options"), will be granted on the Second Grant Date (as defined below).
Tools for this story
Each opens in a new tab, filled in for Staar Surgical Co. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.